nach oben

Erschienen in:

01.01.2011 | Original Article

Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey

verfasst von: Ryogo Minamimoto, Michio Senda, Takashi Terauchi, Seishi Jinnouchi, Tomio Inoue, Takeshi Iinuma, Takeshi Inoue, Kengo Ito, Hiroshi Iwata, Kimiichi Uno, Shinya Oku, Kazuhiro Oguchi, Eriko Tsukamoto, Rumi Nakashima, Sadahiko Nishizawa, Hiroshi Fukuda, Takeshi Murano, Tsuyoshi Yoshida

Erschienen in: Annals of Nuclear Medicine | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Objective

The most distinctive feature of FDG-PET cancer screening program is the ability to find various kinds of malignant neoplasms in a single test. The aim of this survey is to clarify the range and frequency of various malignant neoplasms detected by FDG-PET cancer screening performed in Japan.

Methods

“FDG-PET cancer screening” was defined as FDG-PET or positron emission tomography and computed tomography (PET/CT) scan with or without other tests performed for cancer screening of healthy subjects. This survey was based on a questionnaire regarding FDG-PET cancer screening. We analyzed the situation of 9 less frequently found malignant neoplasms including malignant lymphoma, malignancy of head and neck, esophagus, hepatobiliary and gallbladder, pancreas, kidney, cervical and uterine, ovary, and bladder.

Results

The detailed information of subjects with the suspected 9 kinds of malignant neoplasms mentioned above in the FDG-PET cancer screening program was studied in a total of 1,219 cases from 212 facilities. A statistical significance between PET/CT and PET was found in relative sensitivity and PPV for renal cell cancer. Malignant lymphoma was frequently of indolent type, suspected head and neck cancers had many false-positive results, and pancreatic cancer detected in this program was often in the advanced stage even in asymptomatic subjects. The recommendation of combined screening modality to PET or PET/CT was as follows: gastric endoscopy for assessing early esophageal cancer; abdominal ultrasound for screening hepatobiliary and gallbladder cancer; pelvic magnetic resonance imaging for assessing gynecological and pelvic cancers; and the CA125 blood test for screening ovarian cancer. Delayed image was helpful depending on the type of suspected malignant neoplasm.

Conclusion

We analyzed various types of malignant neoplasms detected by the FDG-PET cancer screening program and presented recommended combination of examinations to cover FDG-PET and PET/CT.

Yeung HW, Schöder H, Smith A, Gonen M, Larson SM. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography studies in cancer patients. Mol Imaging Biol. 2005;7:229–35.CrossRefPubMed

Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging. 2006;50:23–7.PubMed

Minamimoto R, Senda M, Uno K, Jinnouchi S, Iinuma T, Ito K, et al. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey. Ann Nucl Med. 2007;21:481–98.CrossRefPubMed

The guideline of FDG-PET cancer screening. Kaku Igaku. 2004; 41:1–21.

The guideline of FDG-PET cancer screening 2007. Kaku Igaku. 2007; 44:1–28.

Kojima S, Zhou B, Teramukai S, Hara A, Kosaka N, Matsuo Y, et al. Cancer screening of healthy volunteers using whole-body 18F-FDG-PET scans: the Nishidai clinic study. Eur J Cancer. 2007;43:1842–8.CrossRefPubMed

Nishizawa S, Kojima S, Teramukai S, Inubushi M, Kodama H, Maeda Y, et al. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report. J Clin Oncol. 2009;27:1767–73.CrossRefPubMed

The Foundation of Cancer Research (FPCR). Cancer Statistics in Japan, 2009.

Schöder H, Gönen M. Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med. 2007;48(Suppl 1):4S–18S.PubMed

10.

Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–51.CrossRefPubMed

11.

Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for staging of patients with indolent non- Hodgkin’s lymphoma. Mol Imaging Biol. 2009;11:269–74.CrossRefPubMed

12.

Wahl RL. Principles and practice of PET and PET/CT. 2nd ed. Lippincott Williams & Wilkins; 2009. p. 221–39.

13.

Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18:3202–10.PubMed

14.

Ott K, Weber WA, Fink U, Helmberger H, Becker K, Stein HJ, et al. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia. World J Surg. 2003;27:1035–9.CrossRefPubMed

15.

Weber G, Morris HP. Comparative biochemistry of hepatomas. III. Carbohydrate enzymes in liver tumors of different growth rates. Cancer Res. 1963;23:987–94.PubMed

16.

De Santis M, Romagnoli R, Cristani A, Cioni G, Casolo A, Vici FF, et al. MRI of small hepatocellular carcinoma: comparison with US, CT, DSA, and Lipiodol-CT. J Comput Assist Tomogr. 1992;16:189–97.CrossRefPubMed

17.

Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology. 2008;51(Suppl 1):34–41.CrossRefPubMed

18.

Stefaniuk P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16:418–24.CrossRefPubMed

19.

Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989;64:1700–7.CrossRefPubMed

20.

Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni PJ, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570–5.CrossRefPubMed

21.

Beger HG, Rau B, Gansauge F, Poch B, Link KH. Treatment of pancreatic cancer: challenge of the facts. World J Surg. 2003;27:1075–84.CrossRefPubMed

22.

Rose DM, Delbeke D, Beauchamp RD, Chapman WC, Sandler MP, Sharp KW, et al. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg. 1999;229:729–37 (discussion).CrossRefPubMed

23.

Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999;40:1784–91.PubMed

24.

Wahl RL. Principles and practice of PET and PET/CT. 2nd ed. Lippincott Williams & Wilkins; 2009. p. 331–47.

25.

Steinberg WM, Gelfand R, Anderson KK, Glenn J, Kurtzman SH, Sindelar WF, et al. Comparison of the sensitivity and specificity of the CA19–9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology. 1986;90:343–9.PubMed

26.

Homma T, Tsuchiya R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int J Pancreatol. 1991;9:119–24.PubMed

27.

Montravers F, Grahek D, Kerrou K, Younsi N, Doublet JD, Gattegno B, et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med. 2000;41:78–84.PubMed

28.

Kopka L, Fischer U, Zoeller G, Schmidt C, Ringert RH, Grabbe E. Dual-phase helical CT of the kidney: value of the corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma. AJR Am J Roentgenol. 1997;169:1573–8.PubMed

29.

Wahl RL. Principles and practice of PET and PET/CT. 2nd ed. Lippincott Williams & Wilkins; 2009. p. 348–54.

30.

Chao A, Chang TC, Ng KK, Hsueh S, Huang HJ, Chou HH, et al. 18F-FDG PET in the management of endometrial cancer. Eur J Nucl Med Mol Imaging. 2006;33:36–44.CrossRefPubMed

31.

Nishizawa S, Inubushi M, Kido A, Miyagawa M, Inoue T, Shinohara K, et al. Incidence and characteristics of uterine leiomyomas with FDG uptake. Ann Nucl Med. 2008;22:803–10.CrossRefPubMed

32.

Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Standardized uptake values of uterine leiomyoma with 18F-FDG PET/CT: variation with age, size, degeneration, and contrast enhancement on MRI. Ann Nucl Med. 2008;22:505–12.CrossRefPubMed

33.

Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266–71.PubMed

34.

Einhorn N, Sjövall K, Knapp RC, Hall P, Scully RE, Bast RC Jr, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992;80:14–8.PubMed

35.

Risum S, Høgdall C, Loft A, Berthelsen AK, Høgdall E, Nedergaard L, et al. The diagnostic value of PET/CT for primary ovarian cancer–a prospective study. Gynecol Oncol. 2007;105:145–9.CrossRefPubMed

36.

Hiatt RA, Ordoñez JD. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev. 1994;3:439–43.PubMed

37.

Kubota K, Itoh M, Ozaki K, Ono S, Tashiro M, Yamaguchi K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696–703.CrossRefPubMed

Titel: Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey
verfasst von: Ryogo Minamimoto
Michio Senda
Takashi Terauchi
Seishi Jinnouchi
Tomio Inoue
Takeshi Iinuma
Takeshi Inoue
Kengo Ito
Hiroshi Iwata
Kimiichi Uno
Shinya Oku
Kazuhiro Oguchi
Eriko Tsukamoto
Rumi Nakashima
Sadahiko Nishizawa
Hiroshi Fukuda
Takeshi Murano
Tsuyoshi Yoshida
Publikationsdatum: 01.01.2011
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 1/2011
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-010-0428-0

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey

Abstract

Objective

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Improvement of image resolution of brain SPECT by use of the wide-angle offset acquisition method

Predictors of abnormal heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT

VEGF-A and its isoform VEGF121 mRNA expression measured by quantitative real-time RT-PCR: correlation with F-18 FDG uptake and aggressiveness of lung adenocarcinoma: preliminary study

Comparative study of anatomical normalization errors in SPM and 3D-SSP using digital brain phantom

Usefulness of the automatic quantitative estimation tool for cerebral blood flow: clinical assessment of the application software tool AQCEL

Diagnostic role of initial renal cortical scintigraphy in children with the first episode of acute pyelonephritis